Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19: a living systematic review of multiple streams of evidence
…, B Rochwerg, D Perri, E Fan, F Stehling… - Annals of internal …, 2020 - acpjournals.org
An update is available for this article. Background: Mechanical ventilation is used to treat
respiratory failure in coronavirus disease 2019 (COVID-19). Purpose: To review multiple …
respiratory failure in coronavirus disease 2019 (COVID-19). Purpose: To review multiple …
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week …
…, W Gleiber, S Naehrig, F Stehling… - The Lancet …, 2022 - thelancet.com
Background Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis
transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe …
transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe …
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function …
…, PD Robinson, H Selvadurai, F Stehling… - American journal of …, 2022 - atsjournals.org
Rationale: The triple-combination regimen elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA)
was shown to be safe and efficacious in children aged 6 through 11 years with cystic fibrosis …
was shown to be safe and efficacious in children aged 6 through 11 years with cystic fibrosis …
Inhalation of Moli1901 in patients with cystic fibrosis
H Grasemann, F Stehling, H Brunar, R Widmann… - Chest, 2007 - Elsevier
… Grasemann, Stehling, and Ratjen have reported to the ACCP that no significant conflicts
of interest exist with any companies/organizations whose products or services may be …
of interest exist with any companies/organizations whose products or services may be …
Sleep disordered breathing in spinal muscular atrophy
Sleep disordered breathing is a common but under-diagnosed complication causing sleep
disturbance and daytime symptoms in children with spinal muscular atrophy. Non-invasive (…
disturbance and daytime symptoms in children with spinal muscular atrophy. Non-invasive (…
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
…, JH Rayment, P Robinson, F Stehling… - American journal of …, 2023 - atsjournals.org
Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and
effective in people with cystic fibrosis (CF) aged ⩾6 years with at least one F508del-CFTR …
effective in people with cystic fibrosis (CF) aged ⩾6 years with at least one F508del-CFTR …
Non‐invasive ventilation on a pediatric intensive care unit: feasibility, efficacy, and predictors of success
C Dohna‐Schwake, F Stehling, E Tschiedel… - Pediatric …, 2011 - Wiley Online Library
Background There is only sparse data on the use of non‐invasive ventilation (NIV) in acute
respiratory failure (ARF) in infants and children. For this setting we investigated feasibility and …
respiratory failure (ARF) in infants and children. For this setting we investigated feasibility and …
ERS statement on paediatric long-term noninvasive respiratory support
…, VP De Sa, M Pons-Odena, F Stehling… - European …, 2022 - Eur Respiratory Soc
Long-term noninvasive respiratory support, comprising continuous positive airway pressure
(CPAP) and noninvasive ventilation (NIV), in children is expanding worldwide, with …
(CPAP) and noninvasive ventilation (NIV), in children is expanding worldwide, with …
Mechanical insufflation/exsufflation improves vital capacity in neuromuscular disorders
F Stehling, A Bouikidis, U Schara… - Chronic respiratory …, 2015 - journals.sagepub.com
Inherited neuromuscular disorders inevitably result in severe lung volume restriction associated
with high morbidity and mortality. The aim of this retrospective study was to evaluate the …
with high morbidity and mortality. The aim of this retrospective study was to evaluate the …
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del …
…, D Staab, W Gleiber, T Pressler, F Stehling… - The Lancet …, 2021 - thelancet.com
Background Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance
regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated …
regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated …